Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-707035 SCHEMBL6095261 | 0.88 | CALCA (0.63) | CALCASMN1; SMN2KCNE1CCR1KCNQ1 | |
| SCHEMBL6093376 | 0.87 | CALCA (0.44) | CALCASMN1; SMN2TP53POLB | |
| SCHEMBL6097052 | 0.83 | CALCA (0.51) | CALCASMN1; SMN2POLB | |
| SCHEMBL6096409 | 0.80 | CALCA (0.53) | CALCATP53KCNE1CCR1KCNQ1 | |
| SCHEMBL6093723 | 0.80 | CALCA (0.49) | CALCASMN1; SMN2TP53POLB | |
| SCHEMBL6095345 | 0.80 | CALCA (0.53) | CALCASMN1; SMN2KCNE1CCR1KCNQ1 | |
| SCHEMBL6095269 | 0.79 | CALCA (0.54) | CALCASMN1; SMN2KCNE1CCR1KCNQ1 | |
| SCHEMBL6094615 | 0.79 | CALCA (0.66) | CALCAKCNE1CCR1KCNQ1CYP2C9 | |
| SCHEMBL6095158 | 0.79 | CALCA (0.52) | CALCATP53KCNE1CCR1KCNQ1 | |
| SCHEMBL6093545 | 0.79 | CALCA (0.63) | CALCATP53CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | CALCA 4716/4885SMN1; SMN2 3629/4885TP53 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.